Searched for
INNOVATIVE LAUNCHES ROCHE
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche pleaThe Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...
- Natco to sell rare spinal disease drug Risdiplam for ₹15,900Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche ...
- Roche Pharma India to appoint Rajwinder Mehdwan as country general managerRoche Pharma India has announced that Rajwinder Mehdwan will take over as the country general manager from April 1, 2025, replacing V Simps...
- Roche launches top selling eye drug Vabysmo in IndiaRoche Pharma India launches Vabysmo, a medication for neovascular age-related macular degeneration and diabetic macular edema in India. The...
- Reliance Lifesciences launches world's first biosimilar used to treat advanced cancersIn 2014, Reliance had entered into a similar arrangement with Torrent Pharma to sell copies of three drugs -- rituximab, adalimumab and cet...
- Zydus Cadila launches copy of Roche’s breast cancer drug HerceptinZydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...
- Delhi HC upholds Roche's patent claims on Tarceva against CiplaIn a statement to ET, Roche said it welcomed the decision of the court, which has upheld the patent covering erlotinib hydrochloride.
- Roche launches new breast cancer drugs in IndiaRoche Products (India) Private Ltd is a wholly owned subsidiary of the Switzerland based Roche Group and has products in therapeutic areas .
- Roche plans to roll out new drugs; plans new market access strategies in India: Maturin Tchoumi, Roche IndiaIndia is a fragmented market and has its own challenges; there is a private sector and public sector. About 80% of the healthcare expenses ...
- Roche plans to step up India play, launches two new medicinesRoche said patients will be offered equated monthly instalment schemes for Perjeta and Kadcyla through financial institutions in the coming...
- India is so big, we can’t ignore it, we always keep it on our radar: Severin Schwan, Roche CEOSchwan says India’s healthcare spend relative to GDP is very low, compared to economies such as China which spends about 5% to 6% of its GD...
- India rejects Swiss drug maker Roche Patent claims on Valcyte againIndian authorities have for the second time rejected Swiss drug maker Roche’s patent claims on valganciclovir, or Valcyte, used to treat an...
- Roche and Cipla enter talks to settle Erlotinib patent rowThe development comes after a division bench of the Delhi HC referred the companies to a mediation that both firms chose to accept.
- Biocon, Mylan challenge ban on using Roche dataBangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...
- Biocon launches breast-cancer drug CANMAbPriced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.
- Biocon ups generic war with nod for Roche's cancer drug cloneBiocon officials confirmed the development to ET but didn't shed light on how soon the company would be ready to bring the biosimilar to th...
- Swiss co Roche loses patent on anti-viral drug ValcyteRoche, a Swiss drugmaker, lost the patent in India on its anti-viral drug Valcyte, widely used by AIDS patients, after the patent office co...
- SC asks Chennai patent office to hear RocheThe SC asked the Chennai patent office to hear and take a final view for all post-grant oppositions for a patent it had granted to Swiss co...
- SC asks Roche not to pursue Cipla case until patent examinationThe Supreme Court (SC) has asked Swiss company Roche not to pursue the patent violation case against the generic version of Cipla’s anti-in...
Load More
